SYS-CON MEDIA Authors: Liz McMillan, Yeshim Deniz, Doug Masi, Mat Mathews, PR.com Newswire

News Feed Item

The Zacks Analyst Blog Highlights: Microsoft, VIVUS, Arena Pharmaceuticals, Orexigen Therapeutics and UCB

CHICAGO, April 19, 2013 /PRNewswire/ -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Microsoft (Nasdaq:MSFT), VIVUS, Inc. (Nasdaq:VVUS), Arena Pharmaceuticals, Inc. (Nasdaq:ARNA), Orexigen Therapeutics, Inc. (Nasdaq:OREX) and UCB (OTC:UCBJF).

(Logo: http://photos.prnewswire.com/prnh/20101027/ZIRLOGO)

Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=5513

Here are highlights from Thursday's Analyst Blog:

Microsoft Posts Strong Earnings

The world's largest software company Microsoft (Nasdaq:MSFT) reported earnings just after the bell, EPS $0.72, surpassing Zacks consensus estimate of $0.67.  Revenues came in just below Zacks estimate of $20.5 billion, at $20.49 billion.

Analysts were concerned about PC sales/demand; Q1 was the fourth consecutive quarter with Y/Y decline in PC sales, the single worse quarter in PC sales history since 1994.  In addition to PC sales, analysts were also concerned with the tepid reception of Windows 8, and weakness in emerging markets.  These issues caused a significant negative agreement amongst covering analysts, but MSFT was able to outperform their expectations.  

The earnings beat caused the stock to jump 1.77% in afterhours trading.  While MSFT beat the earnings consensus estimates, expense management was the major driver in the strong earnings numbers.  Furthermore, revenue growth remains a major concern for future quarters, as well as the disappointing Windows 8 OS.  The combination of these two factors, have analysts worried that there is no clear option as a driver of future growth over the near term.

While Microsoft has attempted to find more avenues for revenues, for example the patent licensing deal with Hon Hai (producer of 40% of the world's consumer electronics), they have not produced a strong game changing product for an elongated period of time.  More significantly, MSFT emergence in the mobile device remains a weakness for the company.

On a positive note, Microsoft continues to reduce costs, and sees decent sales of their Windows 7 and 8 operating systems.   

Expanded Access for VVUS' Qsymia

VIVUS, Inc. (Nasdaq:VVUS) recently announced that the amendment and modification to the Risk Evaluation and Mitigation Strategy (REMS) of its obesity drug, Qsymia (phentermine and topiramate extended-release) has been approved by the US Food and Drug Administration (FDA).

As per the modification to the REMS, Qsymia can now be distributed through certified retail pharmacies apart from the existing certified mail-order pharmacy network. VIVUS had launched Qsymia through some of the leading home delivery networks. We believe the approval of the amended REMS will increase access to Qsymia and thus boost sales.

We remind investors that Qsymia, VIVUS' sole marketed product, was launched in Sep 2012. The FDA cleared Qsymia in Jul 2012 as an adjunct to a healthy diet (low on calories) and increased physical activity for chronic weight management in obese (Body Mass Index, or BMI - 30 or more) or overweight (BMI - 27 or more) adults suffering from at least one weight-related co-morbid condition.

Qsymia revenues in the fourth quarter of 2012 were only $2 million. The uptake has been slow due to the high out-of-pocket cost burden on patients owing to a lack of reimbursement for the product. Although, the company is working on resolving the issue, we believe that it may take some time given that obesity is a new and underdeveloped market.

We remind investors that apart from Qsymia, another weight-loss drug, Arena Pharmaceuticals, Inc. (Nasdaq:ARNA) Belviq, also received approval in the US last year. Orexigen Therapeutics, Inc. (Nasdaq:OREX) is also developing a candidate, Contrave, targeting the lucrative obesity market.

VIVUS, a biopharmaceutical company, carries a Zacks Rank #3 (Hold). Biopharma stocks that currently look attractive include companies like UCB (OTC:UCBJF) carrying a Zacks Rank #1 (Strong Buy).

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today: http://at.zacks.com/?id=5517

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leon Zacks. As a PhD from MIT Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=5518.

Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.

Follow us on Twitter: http://twitter.com/zacksresearch

Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts

Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.

Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
[email protected]
http://www.zacks.com

SOURCE Zacks Investment Research, Inc.

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.